Le Lézard
Classified in: Health
Subject: SVY

Anpac Bio Surpasses 50,000 Case Study Milestone



SACRAMENTO, Calif., Oct. 17, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Described as "game changing" and receiving the, "Breakthrough Innovation Award", at World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection. By analyzing simple, in vitro, liquid or "Blood Biopsies", and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from the 50,000+ cases processed to date indicate Anpac Bio's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 75%-90% for over 26+ different types of cancer ? most at the disease's earliest stages.

The company has filed over 160 CDA-related patent applications worldwide ? 64+ issued currently; and maintains operations in six sites, employing over 100 people globally.

"Since our company launched in 2008, Anpac Bio has pioneered the 'liquid biopsy' space," states Dr. Yu. "Because our CDA devices have already been approved by international regulatory bodies, and our research has been published and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in great demand right now. We've processed over 50,000 CDA tests for individuals; and organizations such as health systems, insurance companies, corporations, and educational institutions. We're very proud our CDA devices have advanced beyond the laboratory, and are processing real tests for real people. And we have dozens of testimonials from people saying our CDA tests detected their early-stage cancer and saved their lives. At this rate, we project to double our CDA cases worldwide and save many more lives in 2018!"

For more information about Anpac Bio please check: www.AnpacBio.com.

 

SOURCE Anpac Bio-Medical Science Company


These press releases may also interest you

at 13:30
One Drop, a leader in the development of digital therapeutics solutions for people with diabetes, today announced the launch of Blood Glucose Prediction and Automated Decision Support. Through these new features, the One Drop | Mobile app will...

at 13:01
New research finds that people with type 1 diabetes (T1D) who used the Diabeloop DBLG1 therapeutic, closed-loop insulin delivery system in a home setting experienced a greater percentage of time in the target blood glucose range and fewer...

at 12:43
When adolescents and adults with type 1 diabetes (T1D) used a new continuous glucose monitoring (CGM) device containing a sensor that can remain implanted in the arm for up to 180 days, the system provided accurate glucose measurement with no major...

at 12:43
A dual-hormone, artificial pancreas1 delivering rapid insulin and the drug pramlintide improved glucose control and reduced glucose variability in adults with type 1 diabetes (T1D) compared to an insulin-only, first-generation artificial pancreas,...

at 12:40
Adults with type 1 diabetes using the Omnipod hybrid closed-loop system (the Horizontm Automated Glucose Control System) were studied in a supervised outpatient hotel setting with unrestricted meals and moderate-intensity exercise and  experienced...

at 10:12
Adults with type 2 diabetes treated with Tresiba® (insulin degludec injection) had a significant reduction in HbA1c and a 30% lower rate of hypoglycaemic episodes after starting basal insulin Findings from CONFIRM - a large real-world evidence (RWE)...




News published on 17 october 2017 at 07:30 and distributed by: